Skip to main content

Table 3 Adverse reactions to postoperative adjuvant chemotherapy in both groups of patients

From: Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer

Toxic reaction Grade 1–2 P Grade 3–4 P
CAPE-OX-CRT group (%) Control group (%) CAPE-OX-CRT group (%) Control group (%)
Diarrhea 10/30 (33.33%) 7/26 (26.92%) 0.602 5/30 (16.67%) 3/26 (11.54%) 0.712
Bone-marrow suppression 22/30 (73.33%) 10/26 (38.46%) 0.008 4/30 (13.33%) 2/26 (7.69%) 0.675
Nausea/vomiting 17/30 (56.67%) 10/26 (38.46%) 0.173 7/30 (23.33%) 3/26 (11.54%) 0.310
Liver dysfunction 4//30 (13.33%) 2/26 (7.69%) 0.303 0 0
Fatigue 20/30 (66.67%) 12/26 (46.15%) 0.121 6/30 (20%) 2/22 (7.69%) 0.263
Peripheral neurotoxic reactions 8/30 (26.67%) 4/26 (15.38%) 0.528 0 0